Primum non nocere does not justify clinical inertia for stroke prevention in elderly patients with atrial fibrillation in the era of direct oral anticoagulants

Published:December 27, 2019DOI:
      Stroke prevention with oral anticoagulation represents the cornerstone of atrial fibrillation (AF) management.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Bo M., Marchionni N.Practical use of direct oral anticoagulants (DOACs) in the older persons with atrial fibrillation. Eur J Intern Med2020; DOI

        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • Ahlsson A.
        • Atar D.
        • Casadei B.
        • Castella M.
        • Diener H.C.
        • Heidbuchel H.
        • Hendriks J.
        • Hindricks G.
        • Manolis A.S.
        • Oldgren J.
        • Popescu B.A.
        • Schotten U.
        • Van Putte B.
        • Vardas P.
        ESC scientific document group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • Malik A.H.
        • Yandrapalli S.
        • Aronow W.S.
        • Panza J.A.
        • Cooper H.A.
        Meta-Analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age.
        Am J Cardiol. 2019; 123: 2051-2057
        • Patti G.
        • Pecen L.
        • Lucerna M.
        • Huber K.
        • Rohla M.
        • Renda G.
        • Siller-Matula J.
        • Ricci F.
        • Kirchhof P.
        • De Caterina R.
        Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation.
        Am J Med. 2019; 132 (e5): 749-757
        • Fumagalli S.
        • Potpara T.S.
        • Bjerregaard Larsen T.
        • Haugaa K.H.
        • Dobreanu D.
        • Proclemer A.
        • Dagres N.
        Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias.
        Results Eur. Heart Rhythm Association Surv. 2017; 19: 1896-1902
        • Patti G.
        • Cavallari I.
        • Hanon O.
        • De Caterina R.
        The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly.
        Int J Cardiol. 2018; 265: 118-124
        • Steinberg B.A.
        • Shrader P.
        • Thomas L.
        • Ansell J.
        • Fonarow G.C.
        • Gersh B.J.
        • Kowey P.R.
        • Mahaffey K.W.
        • Naccarelli G.
        • Reiffel J.
        • Singer D.E.
        • Peterson E.D.
        • Piccini J.P.
        ORBIT-AF investigators and patients. off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the orbit-af ii registry.
        J Am Coll Cardiol. 2016; 68: 2597-2604
        • Fumagalli S.
        • Said S.A.M.
        • Laroche C.
        • Gabbai D.
        • Marchionni N.
        • Boriani G.
        • Maggioni A.P.
        • Popescu M.I.
        • Rasmussen L.H.
        • Crijns H.J.G.M.
        • Lip G.Y.H.
        EORP-AF investigators. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: the EORP-AF general pilot registry (EURObservational research programme-atrial fibrillation).
        JACC Clin Electrophysiol. 2015; 1: 326-334
        • Bo M.
        • Grisoglio E.
        • Brunetti E.
        • Falcone Y.
        • Marchionni N.
        Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence.
        Eur J Intern Med. 2017; 41: 18-27
        • Patti G.
        • Lucerna M.
        • Pecen L.
        • Siller-Matula J.M.
        • Cavallari I.
        • Kirchhof P.
        • De Caterina R.
        Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the prefer in AF (PREvention oF thromboembolic events-European registry in atrial fibrillation).
        J Am Heart Assoc. 2017; : 6
        • Cavallari I.
        • Patti G.
        Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation.
        Anatol J Cardiol. 2018; 19: 67-71
        • Reddy V.Y.
        • Gibson D.N.
        • Kar S.
        • et al.
        Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation.
        J Am Coll Cardiol. 2017; 69: 253-261

      Linked Article

      • Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation.
        European Journal of Internal MedicineVol. 71
        • Preview
          Direct Oral Anticoagulants (DOACs) consistently demonstrated a greater net clinical benefit compared to Vitamin K Antagonists (VKAs) also in persons aged 75 years and over, who account for the largest proportion of AF patients; however, major uncertainties in DOACs prescription have to do with this age group. In this review, persistent uncertainties and implications of frailty and geriatric syndromes on DOACs prescription, and practical use of DOACs in real-world older persons, and will be discussed.
        • Full-Text
        • PDF